Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 4
1994 1
1995 2
1996 6
1998 1
1999 1
2000 1
2001 2
2002 2
2004 2
2006 1
2007 5
2010 2
2011 1
2013 3
2014 7
2015 4
2016 2
2017 5
2019 4
2020 5
2021 4
2022 3
2023 5
2024 3
2025 6
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Ondansetron for irritable bowel syndrome with diarrhoea: randomised controlled trial.
Gunn D, Topan R, Fried R, Holloway I, Brindle R, Hartley S, Barnard L, Corsetti M, Scott SM, Farmer A, Akbar A, Eugenicos M, Trudgill N, Kapur K, McLaughlin J, Sanders DS, Ramadas A, Whorwell P, Houghton L, Dinning PG, Aziz Q, Ford AC, Farrin A, Spiller R. Gunn D, et al. Southampton (UK): National Institute for Health and Care Research; 2023 Oct. Southampton (UK): National Institute for Health and Care Research; 2023 Oct. PMID: 37931046 Free Books & Documents. Review.
Ondansetron, a 5-hydroxytryptamine-3 receptor antagonist, has been shown to benefit patients with irritable bowel syndrome with diarrhoea. ...A previous small study suggested ondansetron benefits patients with irritable bowel sy …
Ondansetron, a 5-hydroxytryptamine-3 receptor antagonist, has been shown to benefit patients with irritable bowel sy …
Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociacion Mexicana de Gastroenterologia, 2024.
Remes-Troche JM, Coss-Adame E, Schmulson M, García-Zermeño KR, Amieva-Balmori M, Carmona-Sánchez R, Gómez-Escudero O, Gómez-Castaños PC, Icaza-Chávez ME, López-Colombo A, Morel-Cerda EC, Valdovinos-Díaz MÁ, Valdovinos-García LR, Villar-Chávez AS. Remes-Troche JM, et al. Rev Gastroenterol Mex (Engl Ed). 2025 Jan-Mar;90(1):77-110. doi: 10.1016/j.rgmxen.2024.10.009. Epub 2025 Apr 29. Rev Gastroenterol Mex (Engl Ed). 2025. PMID: 40307155 Free article. Review.
INTRODUCTION: The aim of this position statement is to provide health professionals with an updated and evidence-based guideline for the pharmacologic management of irritable bowel syndrome (IBS) in Mexico. MATERIAL AND METHODS: A literature review was conduc …
INTRODUCTION: The aim of this position statement is to provide health professionals with an updated and evidence-based guideline for the pha …
Mucosal Serotonin Reuptake Transporter Expression in Irritable Bowel Syndrome Is Modulated by Gut Microbiota Via Mast Cell-Prostaglandin E2.
Gao J, Xiong T, Grabauskas G, Owyang C. Gao J, et al. Gastroenterology. 2022 Jun;162(7):1962-1974.e6. doi: 10.1053/j.gastro.2022.02.016. Epub 2022 Feb 12. Gastroenterology. 2022. PMID: 35167867 Free PMC article.
BACKGROUND & AIMS: Increased colonic serotonin (5-HT) level and decreased serotonin reuptake transporter (SERT) expression in irritable bowel syndrome (IBS) may contribute to diarrhea and visceral hypersensitivity. ...METHODS: C57Bl/6 mice received intrac …
BACKGROUND & AIMS: Increased colonic serotonin (5-HT) level and decreased serotonin reuptake transporter (SERT) expression in irritab …
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.
Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrén M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G. Savarino E, et al. United European Gastroenterol J. 2022 Jul;10(6):556-584. doi: 10.1002/ueg2.12259. Epub 2022 Jun 13. United European Gastroenterol J. 2022. PMID: 35695704 Free PMC article. Review.
Irritable bowel syndrome with diarrhoea (IBS-D) and functional diarrhoea (FDr) are the two major functional bowel disorders characterized by diarrhoea. ...A weak or conditional recommendation was achieved for antispasmodics, probiotics, tryciclic antid …
Irritable bowel syndrome with diarrhoea (IBS-D) and functional diarrhoea (FDr) are the two major functional bowel …
Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.
Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, Corsetti M, Scott M, Farmer A, Kapur K, Sanders D, Eugenicos M, Trudgill N, Whorwell P, Mclaughlin J, Akbar A, Houghton L, Dinning PG, Aziz Q, Ford AC, Farrin AJ, Spiller R. Gunn D, et al. Aliment Pharmacol Ther. 2023 Jun;57(11):1258-1271. doi: 10.1111/apt.17426. Epub 2023 Mar 3. Aliment Pharmacol Ther. 2023. PMID: 36866724 Free article.
BACKGROUND: Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS-D). AIM: To conduct a 12-week parallel group, randomised, double-blind, placebo-controlled trial of ondansetron 4 mg o.d. ...On intention-to-treat analysis …
BACKGROUND: Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS-D). AIM: To conduct a …
Drugs for Irritable Bowel Syndrome.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Mar 23;62(1594):25-32. Med Lett Drugs Ther. 2020. PMID: 32324172 No abstract available.
Best management of irritable bowel syndrome.
Black CJ, Ford AC. Black CJ, et al. Frontline Gastroenterol. 2020 May 28;12(4):303-315. doi: 10.1136/flgastro-2019-101298. eCollection 2021. Frontline Gastroenterol. 2020. PMID: 34249316 Free PMC article. Review.
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction which can have a considerable impact on quality of life. ...For patients with diarrhoea, the 5-hydroxytryptamine-(3) receptor agonists alosetron and ramosetron appear to be the most …
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction which can have a considerable impact on qu …
Chronic, Noninfectious Diarrhea: A Review.
Singh P, Lee A, Sheth NM, Chey WD. Singh P, et al. JAMA. 2026 Apr 14;335(14):1250-1262. doi: 10.1001/jama.2026.0872. JAMA. 2026. PMID: 41770539 Review.
OBSERVATIONS: The most common causes of chronic, noninfectious diarrhea are irritable bowel syndrome with diarrhea (IBS-D) and functional diarrhea. IBS-D typically presents with recurrent abdominal pain relieved or worsened after defecation. Functional diarrh …
OBSERVATIONS: The most common causes of chronic, noninfectious diarrhea are irritable bowel syndrome with diarrhea (IBS …
Ondansetron and irritable bowel syndrome.
Luthra P, Ford AC. Luthra P, et al. Gut. 2015 Jul;64(7):1181. doi: 10.1136/gutjnl-2014-307551. Epub 2014 May 20. Gut. 2015. PMID: 24846912 Free article. No abstract available.
82 results